Stock Track | Kodiak Sciences Soars 5.02% as H.C. Wainwright Raises Price Target

Stock Track11-17

Shares of Kodiak Sciences Inc. (KOD) are soaring 5.02% in pre-market trading on Monday, following a series of analyst actions, most notably a price target increase from H.C. Wainwright. The biotechnology company, which focuses on novel therapeutics to treat retinal diseases, is seeing increased investor interest amid these analyst updates.

H.C. Wainwright has raised its price target for Kodiak Sciences from $24 to $26, maintaining a Buy rating on the stock. This upward revision suggests growing confidence in the company's potential. Additionally, other firms have weighed in on KOD, with Barclays maintaining a Hold rating and setting a price target of $17.00, while Chardan Capital reiterated its Neutral stance on the stock.

The divergent views from analysts highlight the complex landscape Kodiak Sciences is navigating in the healthcare sector. While some see significant upside potential, others remain cautious. Investors appear to be responding positively to the optimistic outlook from H.C. Wainwright, driving the stock's pre-market surge. As the market digests these various analyst perspectives, it will be crucial to monitor how Kodiak Sciences' pipeline developments and financial performance align with these expectations in the coming months.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1131928204?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 23:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1131928204","market":"hk","top_or_hot":-1,"title":"Stock Track | Kodiak Sciences Soars 5.02% as H.C. Wainwright Raises Price Target","media":"Stock Track","content":"<p>Shares of Kodiak Sciences Inc. (KOD) are soaring 5.02% in pre-market trading on Monday, following a series of analyst actions, most notably a price target increase from H.C. Wainwright. The biotechnology company, which focuses on novel therapeutics to treat retinal diseases, is seeing increased investor interest amid these analyst updates.</p>\n\n<p>H.C. Wainwright has raised its price target for Kodiak Sciences from $24 to $26, maintaining a Buy rating on the stock. This upward revision suggests growing confidence in the company's potential. Additionally, other firms have weighed in on KOD, with Barclays maintaining a Hold rating and setting a price target of $17.00, while Chardan Capital reiterated its Neutral stance on the stock.</p>\n\n<p>The divergent views from analysts highlight the complex landscape Kodiak Sciences is navigating in the healthcare sector. While some see significant upside potential, others remain cautious. Investors appear to be responding positively to the optimistic outlook from H.C. Wainwright, driving the stock's pre-market surge. As the market digests these various analyst perspectives, it will be crucial to monitor how Kodiak Sciences' pipeline developments and financial performance align with these expectations in the coming months.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Kodiak Sciences Soars 5.02% as H.C. Wainwright Raises Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Kodiak Sciences Soars 5.02% as H.C. Wainwright Raises Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-17 23:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Kodiak Sciences Inc. (KOD) are soaring 5.02% in pre-market trading on Monday, following a series of analyst actions, most notably a price target increase from H.C. Wainwright. The biotechnology company, which focuses on novel therapeutics to treat retinal diseases, is seeing increased investor interest amid these analyst updates.</p>\n\n<p>H.C. Wainwright has raised its price target for Kodiak Sciences from $24 to $26, maintaining a Buy rating on the stock. This upward revision suggests growing confidence in the company's potential. Additionally, other firms have weighed in on KOD, with Barclays maintaining a Hold rating and setting a price target of $17.00, while Chardan Capital reiterated its Neutral stance on the stock.</p>\n\n<p>The divergent views from analysts highlight the complex landscape Kodiak Sciences is navigating in the healthcare sector. While some see significant upside potential, others remain cautious. Investors appear to be responding positively to the optimistic outlook from H.C. Wainwright, driving the stock's pre-market surge. As the market digests these various analyst perspectives, it will be crucial to monitor how Kodiak Sciences' pipeline developments and financial performance align with these expectations in the coming months.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KOD","symbol_name":"Kodiak Sciences Inc.","start_time":0,"source_url":"","article_id":"1131928204","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1131928204","pubTimestamp":1763392110,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Kodiak Sciences Inc. (KOD) are soaring 5.02% in pre-market trading on Monday, following a series of analyst actions, most notably a price target increase from H.C. Wainwright. The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KOD":"Kodiak Sciences Inc."},"translate_title":"股票追踪|科迪亚克科学飙升5.02%。温赖特提高价格目标","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KOD":1},"content_text":"Shares of Kodiak Sciences Inc. (KOD) are soaring 5.02% in pre-market trading on Monday, following a series of analyst actions, most notably a price target increase from H.C. Wainwright. The biotechnology company, which focuses on novel therapeutics to treat retinal diseases, is seeing increased investor interest amid these analyst updates.\nH.C. Wainwright has raised its price target for Kodiak Sciences from $24 to $26, maintaining a Buy rating on the stock. This upward revision suggests growing confidence in the company's potential. Additionally, other firms have weighed in on KOD, with Barclays maintaining a Hold rating and setting a price target of $17.00, while Chardan Capital reiterated its Neutral stance on the stock.\nThe divergent views from analysts highlight the complex landscape Kodiak Sciences is navigating in the healthcare sector. While some see significant upside potential, others remain cautious. Investors appear to be responding positively to the optimistic outlook from H.C. Wainwright, driving the stock's pre-market surge. As the market digests these various analyst perspectives, it will be crucial to monitor how Kodiak Sciences' pipeline developments and financial performance align with these expectations in the coming months.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1131928204","isCrawlerRequest":true}